EW · Edwards Lifesciences Corp
Price
Snapshot
50 fields · last close| Market Cap | $51.75B |
| P/E | 51.53 |
| Float | 573.4M |
| Beta | 0.84 |
| Volatility | 21.1% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 83 |
| Price | 89.80 |
| Change | +0.02% |
| Prev Close | 89.78 |
| Open | 91.08 |
| Day Low | 89.33 |
| Day High | 91.53 |
| Avg Vol | 3 |
| Avg $ Vol | $248.1M |
| 52W High | 96.29 |
| 52W Low | 72.30 |
| 52W Pos | 72.9% |
| From High | −6.74% |
| From Low | +24.20% |
| Max DD 1Y | −13.19% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.36% |
| SMA 50 | +0.19% |
| SMA 200 | +5.74% |
| RSI (14) | 48.7 |
| Vol 30D | 20.1% |
| Vol 90D | 24.4% |
| 1Y Range | 72–96 |
| Daily bars | 506 |
| Perf Week | −0.19% |
| Perf Month | +0.91% |
| Perf Quarter | +2.66% |
| Perf Half Y | +7.02% |
| Perf Year | +10.54% |
| Perf YTD | +5.24% |
| Prev Day | +0.02% |
| Clavix | A- |
| Debt / Eq | 0.06 |
| Curr Ratio | 3.72 |
| Int Cover | 110.0× |
| FCF Margin | 22.0% |
| Rev Growth | +0.1% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 4 / 47 |
What EW does
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Clavix risk grade
regraded every trading dayEW grades A-, 83 of 100. Steadiest on Macro Resilience (70), most exposed on News Sentiment (64, mixed). 3 of the 4 weighted dimensions sit above the Health Care median. Ranks 4 of 47 in Health Care by Clavix score.
How rough the ride is
| EW | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.84 | 0.81 |
| Volatilityannualized | 21.1% | 20.4% |
| Max drawdown, past yearworst peak-to-trough fall | −13.2% | — |
| Typical daily movemedian absolute daily change | 0.87% | — |
| Days beyond ±3%of the last 252 sessions | 166% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| EW | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.84 | 0.81 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| EW | |
|---|---|
| 1 week | −0.2% |
| 1 month | +0.9% |
| Year to date | +5.2% |
| 1 year | +10.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| EW | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 23 Jul |
| Average score0 most bearish, 100 most bullish | 62 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 4 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| EW | |
|---|---|
| Revenue growthyear over year | +0.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Health Care
47 companies| Metric | EW | Sector spread | Median |
|---|---|---|---|
| Beta | 0.84 | 0.81 | |
| Volatility | 21.1% | 20.4% | |
| P/E | 51.53 | 26.14 | |
| Debt / equity | 0.06 | 0.71 | |
| Current ratio | 3.72 | 1.58 | |
| FCF margin | 22.0% | 8.6% | |
| Interest coverage | 110.0× | 6.3× |
Recent news
most recent scored articles · the chip is the article’s score · click to openEdwards Lifesciences announced that Corporate Vice President Donald E. Bobo Jr., a longtime leader of the company's strategy and corporate development efforts, plans to retire in mid-2027, and a succession process is already underway.
Edwards Lifesciences filed an 8-K on August 28, 2026 disclosing that Donald E. Bobo, Jr., Corporate Vice President of Strategy and Corporate Development, plans to retire from the company by mid-year 2027. The company will begin a search for his successor, with a transition of duties expected during 2027, and Mr. Bobo is also expected to remain as a consultant through the end of 2027.
Meiji Yasuda Asset Management bought a new position in Edwards Lifesciences during the second quarter, purchasing 53,418 shares, according to its Form 13F filing with the SEC. The article body is truncated and does not include further details.
The article evaluates Edwards Lifesciences as a portfolio holding, noting that growth in its TAVR (a non-surgical aortic valve replacement procedure) and TMTT (non-surgical mitral and tricuspid valve therapies) businesses supports the outlook, while currency headwinds and intense competition remain key risks. The body is a single summary sentence with no specific numbers, dates, or events reported.
An analysis piece weighing whether to hold Edwards Lifesciences stock, noting that growth in its TAVR (less-invasive aortic valve replacement) and TMTT (treatments for leaking mitral and tricuspid valves) businesses supports the outlook, while currency pressure and heavy competition remain key risks.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BDX | Becton Dickinson and Co | A- | $51.11B | 54.01 | 0.24 | Compare |
| HUM | Humana Inc | B | $48.82B | 37.87 | 0.68 | Compare |
| MDLN | Medline Inc | B | $48.11B | 67.50 | 0.78 | Compare |
| CAH | Cardinal Health Inc | A- | $57.82B | 33.59 | 0.54 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $41.70B | 36.69 | 1.57 | Compare |
| COR | Cencora Inc | B+ | $64.35B | 24.52 | 0.59 | Compare |
| BSX | Boston Scientific Corp | B | $68.04B | 18.98 | 0.59 | Compare |
| CI | Cigna Group | B+ | $75.64B | 11.64 | 0.27 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.